Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
Multiple Sclerosis and Related Disorders|March 20, 2015
Do neutralising antibodies against exogenous interferon-beta inhibit endogenous signalling pathways?Debra Fine, Abhishek Dattani, Isabel Moreira, et al.
Multiple Sclerosis and Related Disorders|July 10, 2020
The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosisDavid Baker, Gareth Pryce, Louisa K James, et al.
Clinical Medicine (London, England)|January 25, 2012
Vitamin D deficiency--do we follow our own advice?Ruth Dobson, Ute C Meier, Monica Marta, et al.
Multiple Sclerosis and Related Disorders|July 22, 2015
Is it time to target no evident disease activity (NEDA) in multiple sclerosis?Gavin Giovannoni, Benjamin Turner, Sharmilee Gnanapavan, et al.
Multiple Sclerosis and Related Disorders|October 8, 2021
Antigen-specific tolerization in human autoimmunity: Inhibition of interferon-beta1a anti-drug antibodies in multiple sclerosis: A case reportMonica Marta, David Baker, Paul Creeke, et al.
Practical Neurology|April 27, 2016
Switching patients at high risk of PML from natalizumab to another disease-modifying therapyGavin Giovannoni, Monica Marta, Angharad Davis, et al.
Neurology|March 22, 2019
Visibility and representation of women in multiple sclerosis researchAlison Thomson, Rachel Horne, Christine Chung, et al.
Arthritis and Rheumatism|April 29, 2008
Profound and paradoxical impact on arthritis and autoimmunity of the rat antigen-presenting lectin-like receptor complexJian Ping Guo, Liselotte Bäckdahl, Monica Marta, et al.
Autoimmunity Reviews|March 15, 2015
The role of infections in Behçet disease and neuro-Behçet syndromeMonica Marta, Ernestina Santos, Ester Coutinho, et al.
Rheumatology (Oxford, England)|January 20, 2012
Development of resistance to biologic therapies with reference to IFN-βRachel A Farrell, Monica Marta, Adriana J Gaeguta, et al.
Pageof 5